Q BioMed (OTCMKTS:QBIO) was downgraded by equities research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a research note issued to investors on Thursday, The Fly reports. They currently have a $1.85 price objective on the stock, down from their prior price objective of $6.75. Roth Capital’s price objective indicates a potential downside of 5.13% from the company’s previous close.
Shares of OTCMKTS:QBIO traded up $0.13 during trading hours on Thursday, reaching $1.95. The stock had a trading volume of 38,124 shares, compared to its average volume of 42,801. Q BioMed has a 1 year low of $1.67 and a 1 year high of $5.90.
Q BioMed Company Profile
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.